AKTX Akari Therapeutics

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Akari Therapeutics, Plc Investors

LOS ANGELES--(BUSINESS WIRE)--

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ: AKTX) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Akari investigation page on our website at www.glancylaw.com/case/akari-therapeutics-plc.

On May 11, 2017, the Company announced that its CEO, Dr. Gur Roshwalb, was placed on administrative leave while the Akari Board of Directors investigates whether Dr. Roshwalb had any involvement with a research report that contained material inaccuracies.

On this news, the Company’s share price fell more than 20% during intraday trading on May 12, 2017.

If you purchased Akari securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
12/05/2017

Underlying

AKTXAkari Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akari Therapeutics

Free Trial
AKTX Akari Therapeut...

Akari Therapeutics Plc: 2 directors

Two Directors at Akari Therapeutics Plc bought 43,600,000 shares at 0.001USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

AKTX AKARI THERAPEUTICS
12/31/24 December 31, 2024 1 EN
 PRESS RELEASE
Free
AKTX Akari Therapeut...

AKARI THERAPEUTICS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Rema...

NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (NasdaqCM: AKTX). Investor losses must relate to purchases of the Company’s securities between March 30, 2017 and May 11, 2017. This action is pending in the United States District Court for the Southern ...

July 8, 2017 1 EN
 PRESS RELEASE
Free
AKTX Akari Therapeut...

AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages I...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Akari American Depository Receipts (“ADRs”) between March 30, 2017 and May 11, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no co...

July 5, 2017 1 EN
 PRESS RELEASE
Free
AKTX Akari Therapeut...

AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages I...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Akari American Depository Receipts (“ADRs”) between March 30, 2017 and May 11, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no co...

June 19, 2017 1 EN
 PRESS RELEASE
Free
AKTX Akari Therapeut...

AKARI THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney Gene...

NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (NasdaqCM: AKTX), if they purchased the Company’s securities between March 30, 2017, and May 11, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York. ...

June 17, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch